Dialogues in Diabetes – Advances in Diabesity Management: A Closer Look at Incretin-Based Multiagonist Therapy (Issue 2)

Overview

Provider Statement

This continuing education activity is provided by

Support Statement

This activity is supported by an educational grant from Lilly.

Activity Description

Type 2 diabetes (T2D) and obesity are responsible for a large global burden of morbidity and mortality in the form of cardiovascular disease, kidney disease, and retinopathy. Obesity is frequently a comorbidity T2D. There is strong and consistent evidence that obesity management can delay progression from prediabetes to T2D and may be beneficial in the treatment of T2D. In patients with overweight and obese with T2D, modest and sustained weight loss has been shown to improve glycemic control and to reduce the need for glucose-lowering medications. There is an increasing need to consider pharmacological approaches to assist weight loss in the so called “diabesity” syndrome. Given the relationship between the pathogenesis of obesity and T2D as well as their significant health consequences, treatment strategies that can induce weight loss while achieving glycemic control are needed. In this 2-part CE ePublication series, "Dialogues in Diabetes – Diabesity Management: Advances in Incretin-Based Multireceptor Agonist Therapy," experts in the fields of T2D and obesity will address key clinical considerations in the management of patients with T2D and obesity. In this issue,"Advances in Diabesity Management: A Closer Look at Incretin-based Multiagonist Therapy," expert faculty will evaluate incretin physiology as well as the latest clinical evidence examining the therapeutic value of incretin-based multireceptor agonism in the future treatment paradigms of obesity, T2D, and other metabolic disorders.

Target Audience

The intended audience for this activity is endocrinologists, obesity specialists, internists, family medicine physicians, general practice physicians, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with type 2 diabetes and obesity.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Identify the role of incretin-based therapies in the maintenance of glycemic control, weight reduction, and other metabolic processes.
• Evaluate incretin physiology and the therapeutic value of incretin-based multireceptor agonism in the future treatment paradigms of obesity, T2D, and other metabolic disorders.
• Review the latest clinical evidence regarding the use of incretin-based therapies in T2D and obesity, including the associated cardiovascular and renal considerations.

Activity Chair

Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL

Faculty

Juan Pablo Frias, MD, FACE
Medical Director and Principal Investigator, Velocity Clinical Research
Los Angeles, CA
Voluntary Assistant Professor of Medicine, University of California, San Diego School of Medicine
San Diego, CA

Jennifer B. Green, MD
Professor of Medicine
Department of Medicine, Division of Endocrinology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Medical Writer

Valerie Zimmerman, PhD

Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, PA-C

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22115873. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 11/30/2022 to 11/29/2023. AAPA reference number: CME-208351.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hour Certificate, or AAPA Category 1 CME Certificate.

Disclosures

Vindico Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair reports the following relationship(s)

Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Consultant: Altimmune, Lilly, Novo Nordisk
Independent Research Contractor: Epitomee

Faculty report the following relationship(s)

Juan Pablo Frias, MD, FACE
Consultant: 89bio, Akero, Altimmune, Axcella, Boehringer Ingelheim, Carmot, Lilly, Merck, Novo Nordisk, Pfizer, Sanofi
Speaker Contracted by Ineligible Company: Lilly, Merck, Sanofi
Independent Research Contractor: 89bio, Akero, AstraZeneca, Boehringer Ingelheim, BMS, IONIS, Janssen, Lilly, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, Sanofi

Jennifer B. Green, MD
Consultant: AstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, Novo Nordisk, Sanofi/Lexicon
Independent Research Contractor (paid to institution): Boehringer Ingelheim/Lilly, Merck

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Planners/Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

The articles in this eMonograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Frias, Green, and Kushner at a virtual recording held on July 21, 2022. The eMonograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com